Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Fish and Richardson
McKesson
Cerilliant
US Department of Justice
Covington
Harvard Business School
Fuji
McKinsey

Generated: October 15, 2018

DrugPatentWatch Database Preview

APOTEX TECHNOLOGIES Company Profile

« Back to Dashboard

What is the competitive landscape for APOTEX TECHNOLOGIES, and what generic alternatives to APOTEX TECHNOLOGIES drugs are available?

APOTEX TECHNOLOGIES has four approved drugs.

There are two US patents protecting APOTEX TECHNOLOGIES drugs.

Summary for APOTEX TECHNOLOGIES
US Patents:2
Tradenames:2
Ingredients:1
NDAs:4

Drugs and US Patents for APOTEX TECHNOLOGIES

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Apotex Technologies PAXIL paroxetine hydrochloride CAPSULE;ORAL 020885-002 Oct 9, 1998 DISCN Yes No 6,063,927*PED ➤ Sign Up Y ➤ Sign Up
Apotex Technologies PAXIL paroxetine hydrochloride TABLET;ORAL 020031-002 Dec 29, 1992 AB RX Yes No ➤ Sign Up ➤ Sign Up
Apotex Technologies PAXIL paroxetine hydrochloride TABLET;ORAL 020031-005 Dec 29, 1992 AB RX Yes Yes ➤ Sign Up ➤ Sign Up
Apotex Technologies PAXIL paroxetine hydrochloride SUSPENSION;ORAL 020710-001 Jun 25, 1997 RX Yes Yes ➤ Sign Up ➤ Sign Up
Apotex Technologies PAXIL paroxetine hydrochloride TABLET;ORAL 020031-003 Dec 29, 1992 AB RX Yes No ➤ Sign Up ➤ Sign Up
Apotex Technologies PAXIL paroxetine hydrochloride TABLET;ORAL 020031-001 Dec 29, 1992 AB RX Yes No ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for APOTEX TECHNOLOGIES

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Apotex Technologies PAXIL paroxetine hydrochloride TABLET;ORAL 020031-004 Dec 29, 1992 6,113,944*PED ➤ Sign Up
Apotex Technologies PAXIL CR paroxetine hydrochloride TABLET, EXTENDED RELEASE;ORAL 020936-001 Feb 16, 1999 5,900,423*PED ➤ Sign Up
Apotex Technologies PAXIL paroxetine hydrochloride CAPSULE;ORAL 020885-004 Oct 9, 1998 6,172,233*PED ➤ Sign Up
Apotex Technologies PAXIL paroxetine hydrochloride CAPSULE;ORAL 020885-001 Oct 9, 1998 6,080,759*PED ➤ Sign Up
Apotex Technologies PAXIL paroxetine hydrochloride TABLET;ORAL 020031-001 Dec 29, 1992 6,113,944*PED ➤ Sign Up
Apotex Technologies PAXIL CR paroxetine hydrochloride TABLET, EXTENDED RELEASE;ORAL 020936-001 Feb 16, 1999 5,789,449*PED ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for APOTEX TECHNOLOGIES drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Extended-release Tablets 37.5 mg ➤ Subscribe 2009-05-19
➤ Subscribe Extended-release Tablets 25 mg ➤ Subscribe 2005-09-09
➤ Subscribe Oral Suspension 10 mg/5 mL ➤ Subscribe 2005-02-10
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Express Scripts
Federal Trade Commission
Johnson and Johnson
Julphar
Dow
Chinese Patent Office
Cerilliant
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.